15-Oct-2026
Market Chameleon (Wed, 7-Oct 7:25 AM ET)
Globe Newswire (Tue, 6-Oct 7:00 AM ET)
Globe Newswire (Thu, 17-Sep 7:00 AM ET)
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Thu, 10-Sep 7:00 AM ET)
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Globe Newswire (Thu, 3-Sep 4:06 PM ET)
Globe Newswire (Mon, 17-Aug 7:00 AM ET)
Market Chameleon (Wed, 12-Aug 5:35 AM ET)
Globe Newswire (Wed, 12-Aug 7:05 AM ET)
Kamada Announces Planned Transition of Chief Financial Officer
Globe Newswire (Wed, 12-Aug 7:00 AM ET)
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Kamada Ltd. - trades on the NASDAQ stock market under the symbol KMDA.
As of October 15, 2026, KMDA stock price climbed to $7.83 with 58,259 million shares trading.
KMDA has a beta of 0.56, meaning it tends to be less sensitive to market movements. KMDA has a correlation of 0.05 to the broad based SPY ETF.
KMDA has a market cap of $451.65 million. This is considered a Small Cap stock.
Last quarter Kamada Ltd. - reported $55 million in Revenue and $.16 earnings per share. This fell short of revenue expectation by $-75 million and exceeded earnings estimates by $.05.
In the last 3 years, KMDA traded as high as $9.35 and as low as $4.08.
The top ETF exchange traded funds that KMDA belongs to (by Net Assets): DISV, DFIS, DFIC, DFAX, IBBQ.
KMDA has outperformed the market in the last year with a return of +25.0%, while the SPY ETF gained +17.2%. In the last 3 month period, KMDA beat the market returning +11.9%, while SPY returned +2.5%. However, in the most recent 2 weeks KMDA has underperformed the stock market by returning -4.5%, while SPY returned +1.0%.
KMDA support price is $7.43 and resistance is $7.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KMDA shares will trade within this expected range on the day.
